Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04305899 · ClinicalTrials.gov registry record · Phase 1

A Study to Compare the Taste and Levels in Blood Plasma of BMS-986165 When Taken as Different Formulations by Healthy Adult Participants

A Phase 1 study, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target

NCT04305899 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 40 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04305899, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target

Study Summary

The purpose of this study is to compare the taste, and the levels in blood plasma of different tablet formulations of BMS-986165 when taken by healthy adults.

Interventions

  • DRUG BMS-986165 Tablet formulation 1
  • DRUG BMS-986165 Tablet formulation 2

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2020-08-31
Est. Completion 2020-11-25
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

What the Registry Record Tells You About NCT04305899

The ClinicalTrials.gov registry entry for NCT04305899 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which BMS-986165 Tablet formulation 1 is the first listed.

NCT04305899 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04305899 about?

NCT04305899 is a clinical study titled "A Study to Compare the Taste and Levels in Blood Plasma of BMS-986165 When Taken as Different Formulations by Healthy Adult Participants". The purpose of this study is to compare the taste, and the levels in blood plasma of different tablet formulations of BMS-986165 when taken by healthy adults.

What is the current status of trial NCT04305899?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2020-08-31. Estimated completion is 2020-11-25.

What interventions are being tested in trial NCT04305899?

The interventions under investigation include: BMS-986165 Tablet formulation 1 (DRUG), BMS-986165 Tablet formulation 2 (DRUG).

Who is sponsoring clinical trial NCT04305899?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.